Skip to main content
Equibles
MRMD logo

MRMD · Marimed Inc. · Metrics

Track MRMD — free

Use MRMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MRMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.06 0.00 (-2.63%) At close · Oct 20
Rebalance outlook locked
Market Cap
$22.97M
Shares
403.04M
Volume · Oct 20 131.65K Avg daily vol (3M) 561.09K

MRMD metrics

94 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.06
Market cap
$22.97M

Price action

20 metrics
Price change (1W)
-9.1%
Price change (30D)
-19.7%
Price change (3M)
-14.9%
Price change (6M)
-19.7%
Price change (YTD)
-39.4%
Price change (1Y)
-62.7%
Trailing year
Price change (5Y)
-93.0%
52-week high
$0.16
52-week low
$0.06
Change from 52-week high
-63.9%
Change from 52-week low
+0.4%
Annualized volatility
90.4%
Annualized volatility (3M)
69.4%
Beta
0.2
RSI (14D)
30.8
Price vs SMA 50
-21.3%
Price vs SMA 200
-25.3%
Avg volume (3M)
560,323
Relative volume
0.4
Average dollar volume
$41,195

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
403.04M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.6×
reciprocal yield 168.5%
EV / EBITDA
15.5×
reciprocal yield 6.5%
EV / EBIT
—
P / sales
0.1×
reciprocal yield 713.1%
P / book
0.5
reciprocal yield 188.2%
FCF yield
34.9%
TTM · current market cap
Buyback yield
—
P / FCF
2.9
reciprocal yield 34.9%
P / operating cash flow
2.5
reciprocal yield 40.4%
Earnings yield
-65.2%

Historical valuation

8 metrics
P / E historical average (3Y)
22.4×
reciprocal yield 4.5%
P / E historical average (5Y)
22.4×
reciprocal yield 4.5%
EV / revenue historical average (3Y)
1.0×
reciprocal yield 105.0%
EV / revenue historical average (5Y)
1.8×
reciprocal yield 57.0%
EV / EBIT historical average (3Y)
274.7×
reciprocal yield 0.4%
EV / EBIT historical average (5Y)
182.6×
reciprocal yield 0.5%
EV / EBITDA historical average (3Y)
11.1×
reciprocal yield 9.0%
EV / EBITDA historical average (5Y)
11.3×
reciprocal yield 8.8%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
35.6%
Operating margin
-1.5%
Trailing 12 months
Net margin
-9.1%
Gross profit (TTM)
$58.37M
Operating profit (TTM)
−$2.38M
Net income (TTM)
−$14.98M
Trailing 12 months
Diluted EPS (TTM)
$-0.05
FCF margin
4.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.41
Gross profit per diluted share (TTM)
$0.15
Operating profit per diluted share (TTM)
$-0.01
EBITDA per diluted share (TTM)
$0.02
Net income per diluted share (TTM)
$-0.04
Operating cash flow per diluted share (TTM)
$0.02
Free cash flow per diluted share (TTM)
$0.02
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.00
Book value per share
$0.13

Growth

11 metrics
Revenue growth YoY
+6.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$163.82M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.5%
Year over year · more shares
Revenue CAGR (3Y)
+6.0%
Revenue CAGR (5Y)
+25.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.7%
Return on assets
-7.6%
Debt / equity
1.9
Current ratio
0.9
EBITDA (TTM)
$6.29M
Free cash flow (TTM)
$8.01M
Quick ratio
0.3
Interest coverage
-0.3
Net debt / EBITDA
11.8
Return on invested capital
—
Trailing 12 months
Net cash
−$74.23M
Latest balance sheet
Cash & equivalents
$8.44M
Total assets
$197.23M
Total debt
$82.67M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$9.27M
Capital expenditures (TTM)
$1.26M
R&D (TTM)
—
SG&A (TTM)
$960,640
Stock compensation (TTM)
$1.44M
R&D / revenue
—
Stock compensation / revenue
0.9%

Ownership (13F)

9 metrics
13F filers
2
13F filer change QoQ
-1
Institutional ownership
0.2%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-0.7%
Holder tenure
22.0
Price vs estimated holder cost
-91.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
13 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1522767 CUSIP 56782V107 Visit website Investor relations